Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Dec;116(8):3149–3157. doi: 10.1111/j.1476-5381.1995.tb15117.x

The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.

D T Beattie 1, I J Beresford 1, H E Connor 1, F H Marshall 1, A B Hawcock 1, R M Hagan 1, J Bowers 1, P J Birch 1, P Ward 1
PMCID: PMC1909174  PMID: 8719789

Abstract

1. The in vitro and in vivo pharmacology of GR203040 ((2S, 3S)-2-methoxy-5-tetrazol-1-yl-benzyl-(2-phenyl-piperidin-3-y l)-amine), a novel, highly potent and selective non-peptide tachykinin NK1 receptor antagonist, was investigated in the present study. 2. GR203040 potently inhibited [3H]-substance P binding to human NK1 receptors expressed in Chinese hamster ovary (CHO) and U373 MG astrocytoma cells, and NK1 receptors in ferret and gerbil cortex (pKi values of 10.3, 10.5, 10.1 and 10.1 respectively). GR203040 had lower affinity at rat NK1 receptors (pKi = 8.6) and little affinity for human NK2 receptors (pKi < 5.0) in CHO cells and NK3 receptors in guinea-pig cortex (pKi < 6.0). With the exception of the histamine H1 receptor (pIC50 = 7.5). GR203040 had little affinity (pIC50 < 6.0) at all non-NK1 receptors and ion channels examined. Furthermore, GR203040 produced only weak inhibition of Na+ currents in SH-SY5Y neuroblastoma and superior cervical ganglion cells (pIC50 values < 4.0). GR203040 produced only weak antagonism of Ca(2+)-evoked contractions of rat isolated portal vein (pKn = 4.1). The enantiomer of GR203040, GR205608 (2R, 3R)-2-methoxy-5-tetrazol-1-yl-benzyl-(2-phenyl-piperidin-3-y l)-amine), had 10,000 fold lower affinity at the human NK1 receptor expressed in CHO cells (pKi = 6.3). 3. In gerbil ex vivo binding experiments, GR203040 produced a dose-dependent inhibition of the binding of [3H]-substance P to cerebral cortical membranes (ED50 = 15 micrograms kg-1 s.c. and 0.42 mg kg-1 p.o.). At 10 micrograms kg-1 s.c., the inhibition of [3H]-substance P binding was maintained for > 6 h. In the rat, GR203040 was less potent (ED50 = 15.4 mg kg-1 s.c.) probably reflecting, at least in part, its lower affinity at the rat NK1 receptor. 4. In guinea-pig isolated ileum and dog isolated middle cerebral and basilar arteries, GR203040 produced a rightward displacement of the concentration-effect curves to substance P methyl ester (SPOMe) with suppression of the maximum agonist response (apparent pKB values of 11.9, 11.2 and 11.1 respectively). 5. In anaesthetized rabbits, GR203040 antagonized reductions in carotid arterial vascular resistance evoked by SPOMe, injected via the lingual artery (DR10 (i.e. the dose producing a dose-ratio of 10) = 1.1 micrograms kg-1, i.v.). At a dose 20 fold greater than its DR10 value (i.e. 22 micrograms kg-1, i.v.), significant antagonism was evident more than 2 h after GR203040 administration. 6. In anaesthetized rats, GR203040 (3 and 10 mg kg-1, i.v.) produced a dose-dependent inhibition of plasma protein extravasation in dura mater, conjunctiva, eyelid and lip in response to electrical stimulation of the trigeminal ganglion. 7. It is concluded that GR203040 is one of the most potent and selective NK1 receptor antagonists yet described, and as such, has considerable potential as a pharmacological tool to characterize the physiological and pathological roles of substance P and NK1 receptors. GR203040 may also have potential as a novel therapeutic agent for the treatment of conditions such as migraine, emesis and pain.

Full text

PDF
3149

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apperley E., Humphrey P. P., Levy G. P. Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br J Pharmacol. 1976 Oct;58(2):211–221. doi: 10.1111/j.1476-5381.1976.tb10398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beattie D. T., Stubbs C. M., Connor H. E., Feniuk W. Neurokinin-induced changes in pial artery diameter in the anaesthetized guinea-pig. Br J Pharmacol. 1993 Jan;108(1):146–149. doi: 10.1111/j.1476-5381.1993.tb13454.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beaujouan J. C., Heuillet E., Petitet F., Saffroy M., Torrens Y., Glowinski J. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108(3):793–800. doi: 10.1111/j.1476-5381.1993.tb12880.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beresford I. J., Birch P. J., Hagan R. M., Ireland S. J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol. 1991 Oct;104(2):292–293. doi: 10.1111/j.1476-5381.1991.tb12423.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beresford I. J., Sheldrick R. L., Ball D. I., Turpin M. P., Walsh D. M., Hawcock A. B., Coleman R. A., Hagan R. M., Tyers M. B. GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors. Eur J Pharmacol. 1995 Jan 16;272(2-3):241–248. doi: 10.1016/0014-2999(94)00655-q. [DOI] [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  7. Buzzi M. G., Moskowitz M. A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol. 1990 Jan;99(1):202–206. doi: 10.1111/j.1476-5381.1990.tb14679.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Caeser M., Seabrook G. R., Kemp J. A. Block of voltage-dependent sodium currents by the substance P receptor antagonist (+/-)-CP-96,345 in neurones cultured from rat cortex. Br J Pharmacol. 1993 Aug;109(4):918–924. doi: 10.1111/j.1476-5381.1993.tb13708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen C. A., Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques. 1988 Jul-Aug;6(7):632–638. [PubMed] [Google Scholar]
  10. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  11. Constantine J. W., Lebel W. S., Woody H. A., Benoit P. A., Wolfgang E. A., Knight D. R. Cardiovascular effects of CP-96,345, a non-peptide blocker of tachykinin NK1 receptors. Eur J Pharmacol. 1994 Feb 11;252(3):275–282. doi: 10.1016/0014-2999(94)90173-2. [DOI] [PubMed] [Google Scholar]
  12. Dam T. V., Quirion R. Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain. Peptides. 1986 Sep-Oct;7(5):855–864. doi: 10.1016/0196-9781(86)90106-3. [DOI] [PubMed] [Google Scholar]
  13. Edvinsson L., McCulloch J., Uddman R. Substance P: immunohistochemical localization and effect upon cat pial arteries in vitro and in situ. J Physiol. 1981 Sep;318:251–258. doi: 10.1113/jphysiol.1981.sp013862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Edvinsson L., Rosendal-Helgesen S., Uddman R. Substance P: localization, concentration and release in cerebral arteries, choroid plexus and dura mater. Cell Tissue Res. 1983;234(1):1–7. doi: 10.1007/BF00217397. [DOI] [PubMed] [Google Scholar]
  15. Emonds-Alt X., Doutremepuich J. D., Heaulme M., Neliat G., Santucci V., Steinberg R., Vilain P., Bichon D., Ducoux J. P., Proietto V. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur J Pharmacol. 1993 Dec 21;250(3):403–413. doi: 10.1016/0014-2999(93)90027-f. [DOI] [PubMed] [Google Scholar]
  16. Gardner C. J., Twissell D. J., Dale T. J., Gale J. D., Jordan C. C., Kilpatrick G. J., Bountra C., Ward P. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol. 1995 Dec;116(8):3158–3163. doi: 10.1111/j.1476-5381.1995.tb15118.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J. F., Blanchard J. C., Laduron P. M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10208–10212. doi: 10.1073/pnas.88.22.10208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gitter B. D., Waters D. C., Bruns R. F., Mason N. R., Nixon J. A., Howbert J. J. Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol. 1991 May 17;197(2-3):237–238. doi: 10.1016/0014-2999(91)90532-u. [DOI] [PubMed] [Google Scholar]
  19. Goadsby P. J., Edvinsson L., Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988 Feb;23(2):193–196. doi: 10.1002/ana.410230214. [DOI] [PubMed] [Google Scholar]
  20. Guard S., Boyle S. J., Tang K. W., Watling K. J., McKnight A. T., Woodruff G. N. The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences. Br J Pharmacol. 1993 Sep;110(1):385–391. doi: 10.1111/j.1476-5381.1993.tb13821.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Guard S., Watson S. P., Maggio J. E., Too H. P., Watling K. J. Pharmacological analysis of [3H]-senktide binding to NK3 tachykinin receptors in guinea-pig ileum longitudinal muscle-myenteric plexus and cerebral cortex membranes. Br J Pharmacol. 1990 Apr;99(4):767–773. doi: 10.1111/j.1476-5381.1990.tb13004.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Heuillet E., Ménager J., Fardin V., Flamand O., Bock M., Garret C., Crespo A., Fallourd A. M., Doble A. Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG. J Neurochem. 1993 Mar;60(3):868–876. doi: 10.1111/j.1471-4159.1993.tb03231.x. [DOI] [PubMed] [Google Scholar]
  23. Kenakin T. P. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev. 1984 Sep;36(3):165–222. [PubMed] [Google Scholar]
  24. Maggi C. A., Patacchini R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol. 1993 Feb;13(1):23–93. doi: 10.1111/j.1474-8673.1993.tb00396.x. [DOI] [PubMed] [Google Scholar]
  25. Markowitz S., Saito K., Moskowitz M. A. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci. 1987 Dec;7(12):4129–4136. doi: 10.1523/JNEUROSCI.07-12-04129.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. McLean S., Ganong A., Seymour P. A., Snider R. M., Desai M. C., Rosen T., Bryce D. K., Longo K. P., Reynolds L. S., Robinson G. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther. 1993 Oct;267(1):472–479. [PubMed] [Google Scholar]
  27. Moskowitz M. A., Buzzi M. G., Sakas D. E., Linnik M. D. Pain mechanisms underlying vascular headaches. Progress Report 1989. Rev Neurol (Paris) 1989;145(3):181–193. [PubMed] [Google Scholar]
  28. Moussaoui S. M., Philippe L., Le Prado N., Garret C. Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580. Eur J Pharmacol. 1993 Jul 20;238(2-3):421–424. doi: 10.1016/0014-2999(93)90879-m. [DOI] [PubMed] [Google Scholar]
  29. Payan D. G., Brewster D. R., Goetzl E. J. Stereospecific receptors for substance P on cultured human IM-9 lymphoblasts. J Immunol. 1984 Dec;133(6):3260–3265. [PubMed] [Google Scholar]
  30. Pernow B. Substance P. Pharmacol Rev. 1983 Jun;35(2):85–141. [PubMed] [Google Scholar]
  31. Regoli D., Nantel F. Pharmacology of neurokinin receptors. Biopolymers. 1991 May;31(6):777–783. doi: 10.1002/bip.360310623. [DOI] [PubMed] [Google Scholar]
  32. Sasaki K., Mizusawa H., Ishidate M., Tanaka N. Regulation of G418 selection efficiency by cell-cell interaction in transfection. Somat Cell Mol Genet. 1992 Nov;18(6):517–527. doi: 10.1007/BF01232648. [DOI] [PubMed] [Google Scholar]
  33. Shepheard S. L., Williamson D. J., Hill R. G., Hargreaves R. J. The non-peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol. 1993 Jan;108(1):11–12. doi: 10.1111/j.1476-5381.1993.tb13432.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Shepheard S. L., Williamson D. J., Williams J., Hill R. G., Hargreaves R. J. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology. 1995 Mar;34(3):255–261. doi: 10.1016/0028-3908(94)00153-j. [DOI] [PubMed] [Google Scholar]
  35. Snider R. M., Constantine J. W., Lowe J. A., 3rd, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991 Jan 25;251(4992):435–437. doi: 10.1126/science.1703323. [DOI] [PubMed] [Google Scholar]
  36. Turcatti G., Ceszkowski K., Chollet A. Biochemical characterization and solubilization of human NK2 receptor expressed in Chinese hamster ovary cells. J Recept Res. 1993;13(1-4):639–652. doi: 10.3109/10799899309073684. [DOI] [PubMed] [Google Scholar]
  37. Wang Z. Y., Tung S. R., Strichartz G. R., Håkanson R. Non-specific actions of the non-peptide tachykinin receptor antagonists, CP-96,345, RP 67580 and SR 48968, on neurotransmission. Br J Pharmacol. 1994 Jan;111(1):179–184. doi: 10.1111/j.1476-5381.1994.tb14041.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES